Posted by 
In a study, a new HIV drug reduced viral replication and increased immune cells in patient with advanced, drug-resistant HIV infection. Used in combination with existing HIV medications, the drug is a promising strategy for patients who have run out of effective treatment options.
For some HIV patients, existing drug therapies fail to suppress the virus, causing drug resistance and worsening condition. FDA approved ibalizumab, a drug that targets the primary receptor for HIV entry into immune cells- CD4 T cells. This novel mechanism of action prevents HIV from entering target cells.
Patients received a dose of ibalizumab, which is delivered intravenously, in addition to their failing regimen, for one week. After that period, they received ibalizumab in combination with optimized treatment regimens for six months. The research team found that after one week on ibalizumab, the majority of the 40 patients (83%) enrolled in the study experienced decrease in viral load, which refers to the amount of HIV detected in the blood.
After 6 months, nearly half of patients saw viral load suppression dip below the level of detection. The researchers also reported an increase in CD4 T cells, which are a marker for immune strength. A single individual experienced an adverse event, which was felt to be ibalizumab-related and resulted in withdrawal from the study.
As the first monoclonal antibody approved to treat HIV, ibalizumab is a promising option for those who have tried several other drug therapies. It should be considered for patients that have multi-drug resistance given because of its efficacy in the study. Because of its novel mechanism, ibalizumab will not interact negatively with other medications. It is also delivered intravenously every two weeks and lasts longer than current HIV drugs, which are taken daily by mouth.